Pfizer applies for emergency use of its Coronavirus vaccine in US
New York: Drug manufacturer Pfizer sought the United States’ health regulators for emergency use authorisation of its potential coronavirus vaccine – one that it is developing with BioNTech.
The company’s Chief Executive Officer Albert Bourla confirmed about the application in a video posted on Pfizer’s official Twitter handle.
“The FDA recognizes that transparency and dialogue are critical for the public to have confidence in COVID-19 vaccines,” the organization’s head Stephen Hahn said in a statement.
“I want to assure the American people that the FDA’s process and evaluation of the data for a potential Covid-19 vaccine will be as open and transparent as possible.”
Bourla expressed confidence that the company would produce 50 million doses of the vaccine by the end of this year, and 1.3 billion of them by the end of 2021.
On Wednesday, Pfizer had announced that the vaccine candidate had demonstrated 95% efficiency in late-phase, or phase 3 trials.